Press "Enter" to skip to content

Anti-tuberculosis Therapeutics Market Outlook 2019 | Shows Industry Overview, Size, Share, Remarkable Growth Factors, Types, and Applications Forecast to 2024


The “Anti-tuberculosis Therapeutics Market” 2019 report provides market size (value and volume), market share, growth rate by types, applications, and combines both qualitative and quantitative methods to make micro and macro forecasts in different regions or countries. Anti-tuberculosis Therapeutics Market report also aims to provide useful and comprehensive insights into current market trends and future growth scenarios. Anti-tuberculosis Therapeutics market report contains information like SWOT analysis, business highlights, strength, weakness, threats and opportunities of industry.

Top Manufacturers of Anti-tuberculosis Therapeutics Market Are:

  • Lupin Limited
  • Macleods Pharmaceuticals Ltd
  • Otsuka Pharmaceutical Co. Ltd
  • Johnson and Johnson
  • Pfizer Inc.
  • Novartis AG

    Get a Sample Copy of the Report –

    Market Overview:

  • The anti-tuberculosis therapeutics market is expected to witness a CAGR of approximately 6.0% over the forecast period, 2019-2024.
  • – Factors, such as the rising prevalence of tuberculosis, a growing initiative from government organization for tuberculosis awareness, a collaboration between academic and private players for novel drug development, and rising incidence of MDR and XDR cases in developing countries, are propelling the growth of the market studied.
  • – According to the WHO’s 2017 Global Tuberculosis Report, approximately 6.3 million new cases of tuberculosis (TB) were reported in 2016. The report also estimated that the new cases corresponded to 61% of the estimated incidence of 10.4 million TB cases. According to WHO, the global treatment success rate in TB treatment was approximately 83%.
  • – Insights from the report mentioned above indicate that around ten countries account for approximately 76% of the total gap between total TB incidence and total TB reporting. The top countries contributing to this gap include India, Indonesia, and Nigeria.
  • – According to WHO, TB is the 9th leading cause of death worldwide and is the leading cause of death from a single infectious agent. The disease causes more deaths than that of HIV/AIDS.
  • – Furthermore, WHO estimates suggests that, in 2016, around 600,000 new cases of rifampicin-resistant (RR) TB were reported worldwide, while the number of new cases of multidrug-resistant (MDR) TB in the same year was estimated to be around 490,000. Approximately 50% of these new TB cases were reported in the regions of India, China, and the Russian Federation.
  • – Overall, the global burden of TB and MDR-TB is a challenge for leading medical regulatory institutions. The active interest of both medical communities and government alike, in curbing TB, is expected to increase the number of diagnoses for TB. This is, in turn, driving the growth of the global anti-tuberculosis therapeutics market, supported by the increasing global prevalence of TB and MDR-TB.<

    Scope of the Report:

  • As per the , Tuberculosis (TB) is a disease affecting the population across the world. Although tuberculosis is a curable disease, it still remains one of the most common causes of death among adults, particularly in emerging economies.

    Anti-tuberculosis Therapeutics Market Report Answers the Following Questions:

    • What will the market size and the growth rate be in 2024?
    • What are the key factors driving the global Anti-tuberculosis Therapeutics market?
    • What are the key market trends impacting the growth of the global Anti-tuberculosis Therapeutics market?
    • What are the challenges to market growth?
    • Who are the key vendors in the global Anti-tuberculosis Therapeutics market?
    • What are the market opportunities and threats faced by the vendors in the global Anti-tuberculosis Therapeutics market?
    • Trending factors influencing the market shares of the relevant regions.
    • What are the key outcomes of the five forces analysis of the global Anti-tuberculosis Therapeutics market?

    For More Information or Query or Customization Before Buying, Visit at –

    Key Market Trends:

    Hospitals/Clinics are Expected to Witness the Fastest Growth in the Coming Future

    The WHO’s strategy to prevent TB includes engaging all relevant healthcare providers in tuberculosis (TB) care, while control through public-private mix approach remains an essential component of the strategy.

    The TB prevalence rate is more in countries, like China, India, and Africa, hence, the governments of these respective countries are trying to decrease the rate by increasing government initiatives and the number of hospitals.

    As an example, China has used partnership between public hospitals and TB dispensaries as one of the strategies to reach the global TB control targets. According to the National Survey conducted in China, it was estimated that there were 203 TB-specific hospitals in China during 1999-2009 and later on, the Chinese government planned to double the number of hospitals.

    The Department of Health of Hong Kong, as of 2015, operated around 17 chest clinics throughout the territory of Hong Kong, providing outpatient service mainly to patients suffering from TB. However, the total attendance at chest clinics decreased from 6,96,300 in 2014 to 6,72,600 in 2015. Most of the TB patients were diagnosed in private hospitals in India as of 2014, which is expected to continue the same way.

    In the coming years, the number of hospitals and clinics for TB is expected to increase further with more government policies, which are a major factor for the growth of the market.

    North America is Expected to be the Largest Market Over the Forecast Period

    As per the Centers for Disease Control and Prevention (CDC), in 2017, a total of 9,093 new cases of tuberculosis (TB) were reported in the United States, representing an incidence rate of 2.8 cases per 100,000 population.

    According to the most recent TB surveillance report the United States continued to make slow progress toward TB elimination in 2016. CDC plays an important role in TB elimination by working with state and local partners in the United States.

    The National Academy of Medicine, the CDC, and many state and local health departments have identified the importance of targeting prevention efforts at people with latent infection. Recently, one of the major priorities of the New York City Department of Health and Mental Hygiene Bureau of Tuberculosis Control was to make sure that individuals at high risk for progression from latent TB infection to TB disease finish the treatment and do not develop the disease.

    The Patient Protection and Affordable Care Act can increase the current efforts to control tuberculosis (TB) in the United States by bringing millions of currently uninsured US citizens into the healthcare system. The US government is also expected to support the collection, analysis, and use of quality-assured data and technologies, such as mobile devices and geographical information services, to find out the best locations for new care and treatment sites, and/or existing sites that should be reinforced, so that appropriate services are widely and easily accessible.

    The anti-tuberculosis therapeutics market is likely to get influenced in the United States, with increasing healthcare expenditure and improved diagnostic strategies by the US government.

    Market Dynamics: –

    • Drivers: (Developing regions and growing markets)
    • Limitations: (Regional, Key Player facing Issues, Future Barriers for growth)
    • Opportunities: (Regional, Growth Rate, Competitive, Consumption)

    The report provides key statistics on the market status of the Anti-tuberculosis Therapeutics Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Anti-tuberculosis Therapeutics .

    Purchase this Report (Price 4250 USD for single user license) –

    Report Objectives:

    • Analyzing the size of the Anti-tuberculosis Therapeutics market on the basis of value and volume.
    • Accurately calculating the market segments, consumption, and other dynamic factors of different sections of the global Anti-tuberculosis Therapeutics market.
    • Determining the key dynamics of the Anti-tuberculosis Therapeutics market.
    • Highlighting significant trends of the Anti-tuberculosis Therapeutics market in terms of manufacture, revenue, and sales.
    • Deeply summarizing top players of the Anti-tuberculosis Therapeutics market and showing how they compete in the industry.
    • Studying industry processes and costs, product pricing, and various trends related to them.
    • Displaying the performance of different regions and countries in the global Anti-tuberculosis Therapeutics market.

    Detailed TOC of Anti-tuberculosis Therapeutics Market Report 2019-2024:

    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study



    4.1 Market Overview
    4.2 Market Drivers
    4.2.1 Rising Prevalence of Tuberculosis
    4.2.2 Growing Initiative from Government Organization for Tuberculosis Awareness
    4.2.3 Collaboration Between Academic and Private Players for Novel Drug Development
    4.2.4 Rising Incidence of MDR and XDR Cases in Developing Countries
    4.3 Market Restraints
    4.3.1 Adverse Side Effects of Anti-tuberculosis Drugs
    4.3.2 High Cost of MDR and XDR TB Drugs
    4.4 Porter’s Five Force Analysis
    4.4.1 Threat of New Entrants
    4.4.2 Bargaining Power of Buyers/Consumers
    4.4.3 Bargaining Power of Suppliers
    4.4.4 Threat of Substitute Products
    4.4.5 Intensity of Competitive Rivalry

    5.1 By Drug Class
    5.1.1 Isoniazid
    5.1.2 Rifampin
    5.1.3 Ethambutol
    5.1.4 Pyrazinamide
    5.1.5 Fluoroquinolones
    5.1.6 Bedaquiline
    5.1.7 Amynoglycosides
    5.1.8 Thioamides
    5.1.9 Cyclic Peptides
    5.1.10 Other Drug Classes
    5.2 By End User
    5.2.1 Hospitals and Clinics
    5.2.2 Government Agencies
    5.2.3 Non Profit Organizations
    5.2.4 Other End Users
    5.3 Geography
    5.3.1 North America United States Canada Mexico
    5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
    5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
    5.3.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
    5.3.5 South America Brazil Argentina Rest of South America

    6.1 Company Profiles
    6.1.1 Lupin Limited
    6.1.2 Macleods Pharmaceuticals Ltd
    6.1.3 Otsuka Pharmaceutical Co. Ltd
    6.1.4 Johnson and Johnson
    6.1.5 Pfizer Inc.
    6.1.6 Novartis AG



    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Renin-Inhibitors Market 2019 Industry Size, Trends Evaluation, Global Growth, Recent Developments and Latest Technology, Future Forecast Research Report 2024

    Cloud Backup & Recovery Software Market 2019 Industry Business Challenges, Share, Geographical Segmentation, Consumption Status and Opportunity Analysis: World Market Outlook to 2023

    Cable Transport Market Current Status 2019 | Size, Share, Trend, Global Demand, Top Companies, Product Category and Forecast to 2023

    Electric Bus Market Global Size | Share Covers Emerging Technologies, Market Growth Rate, CAGR%, Development History, Forecast 2019 to 2024

  • Be First to Comment

    Leave a Reply

    Your email address will not be published. Required fields are marked *